论文部分内容阅读
多塞平为常用三环类抗抑郁药,美国食品和药物管理局新批准其3 mg和6 mg用于失眠症的治疗。小剂量多塞平(≤10 mg)临床治疗失眠有效、耐受良好且无明显不良反应,可作为治疗成年或老年患者以睡眠维持困难为特征的失眠的新选择。本文拟从小剂量多塞平具有高选择性组胺H1受体拮抗作用这一有别于其他催眠药的作用机制并结合临床研究结果,对其应用于失眠症治疗的有效性和安全性进行综述。
Doxepin is a commonly used tricyclic antidepressant and the United States Food and Drug Administration has newly approved its 3 mg and 6 mg for the treatment of insomnia. Small doses of doxepin (≤ 10 mg) is clinically effective in treating insomnia, is well tolerated and has no significant adverse effects and may be used as a new option for treating insomnia characterized by difficulty in maintaining sleep in adults or the elderly. This article is intended to review the efficacy and safety of low dose doxepin in the treatment of insomnia with high selective histamine H1 receptor antagonism, which is different from other hypnotics and the clinical research results. .